Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 2014. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 631,000 Ordinary Shares on June 3, 2014.
- Price Range: Highest price paid was 1,594.50 pence; lowest price paid was 1,580.50 pence.
- Treasury Holdings (Settled): 495,272,414 shares (9.26% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,151,414 shares (10.24% of current total voting rights).
- Shares in Issue: 4,855,424,948 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 631,000 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.24% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, forward-looking outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure regarding share repurchases under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in treasury (495,272,414 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.24% held in treasury including unsettled shares) for disclosure threshold assessments.
- Note that the 4,855,424,948 shares in issue serve as the denominator for shareholder notification requirements.